Quantitative accuracy of 177Lu SPECT reconstruction using different compensation methods: phantom and patient studies
© Hippeläinen et al. 2016
Received: 30 November 2015
Accepted: 9 February 2016
Published: 18 February 2016
In targeted radionuclide therapy (TRT), accurate quantification using SPECT/CT images is important for optimizing radiation dose delivered to both the tumour and healthy tissue. Quantitative SPECT images are regularly reconstructed using the ordered subset expectation maximization (OSEM) algorithm with various compensation methods such as attenuation (A), scatter (S) and detector and collimator response (R). In this study, different combinations of the compensation methods are applied during OSEM reconstruction and the effect on the 177Lu quantification accuracy is studied in an anthropomorphic torso phantom. In addition, the phantom results are reflected to (177)Lu-DOTA-Tyr3-octreotate (177Lu-DOTATATE)-treated patient data and kidney absorbed dose estimates.
The torso phantom was imaged with nine various sized (0.4–104.4 cm3) spherical inserts, filled with known 177Lu activity ranging from 0.5 to 105.5 MBq. Images were reconstructed using OSEM algorithm using A, AR and ARS compensation method combinations. The compensation method combinations were compared by calculating the concentration recovery coefficient (cRC) for each insert. In addition, ten 177Lu-DOTATATE-treated patient’s post-therapy dosimetry acquisitions were reconstructed, and the absorbed dose to kidneys was estimated.
cRC values depend on the insert size for all compensation methods. AR and ARS produced significantly higher cRC values than attenuation correction alone. There were no cRC value differences between the methods for the smallest 1-cm-diameter insert, cRC being 0.18. However, the collimator and detector response compensation method (R) made the 1.3-cm-diameter insert clearly visible and improved cRC estimate from 0.19 to 0.43. ARS produced slightly higher cRC values for small- and medium-sized inserts than AR. On the patient data, a similar trend could be seen. AR and ARS produced higher kidney activities than using attenuation correction alone; the total absorbed doses to the right and left kidneys were on average 15 and 20 % higher for AR and 19 and 25 % higher for ARS, respectively. The effective half-life decay estimated from time-activity curves however showed no notable difference between the compensation methods.
The highest cRC values were achieved by applying ARS compensation during reconstruction. The results were notably higher than those using attenuation correction alone. Similarly, higher activity estimates and thus higher absorbed dose estimates were found in patient data when all compensation methods were applied. ARS improved cRC especially in small-sized sources, and it thus might aid tumour dosimetry for 177Lu PRRT treatments.
The 177Lu-labelled somatostatin analogues (177)Lu-DOTA-Tyr3-octreotide (177Lu-DOTATOC) and (177)Lu-DOTA-Tyr3-octreotate (177Lu-DOTATATE) are used for peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumours (NETs), which are a group of tumours characterized by overexpression of somatostatin receptors. Although both radiopharmaceuticals have been reported to have very high affinity to somatostatin receptors  and high tumour accumulation , kidney doses have also been reported to be high and widely variable between patients [2, 3]. Therefore, patient specific post-therapeutic dosimetry should be performed to ensure patient safety. Dosimetry should be extended from the kidney alone to the tumour as demonstrated in Ilan et al.  to further our understanding of the PRRT dose response as well as to target the treatments to specific patients who could benefit from them.
Absorbed dose calculation of 177Lu-labelled radiopharmaceuticals is based on activity distribution quantification using single photon emission imaging combined with computed tomography (SPECT/CT). In addition to highly ionizing beta radiation that produces about 96 % of the absorbed dose , 177Lu also emits low and medium energy γ radiations that can be imaged using a SPECT/CT system. Activity quantification from SPECT images is not a trivial task. Inaccuracies in image reconstruction and thus in radionuclide uptake estimates are introduced through photon attenuation, scattering, and collimator blurring. Iterative reconstruction techniques allow effective methods for compensation, namely attenuation correction (A), scatter correction (S) and collimator-detector response (R) compensation [6–8], and thus are used in different combinations in quantitative targeted radionuclide therapy (TRT) imaging.
The ordered subsets expectation maximization (OSEM) algorithm  has been widely used for quantitative reconstruction and internal dosimetry calculations. It has been studied using different combinations of compensation methods, and average quantification error has been reported to be from low (1 %) to moderate (20 %) . The results depend on many factors such as source size and shape, isotope and activity concentration of source and background, which increases complexity and also makes comparison between published results difficult. 177Lu radionuclide quantification accuracy has not been studied very extensively [11–14] even though a large number of patients have been treated with 177Lu-labelled somatostatin analogues. Recently, Sanders et.al  validated a 177Lu quantitative SPECT/CT imaging protocol in vivo using urine samples, implementing the method published earlier by Zeintl et al. . In the work of Sanders et.al, the mean error in activity concentration estimated from patients using SPECT/CT was 10.1 ± 8.3 % (range, −19.4 to 22.4 %). The activity estimates were done at one time point after 177Lu-DOTATATE therapy injection, and no estimation was made of the effect of degraded image statistics at later time points on the quantification accuracy. Sanders et.al concluded that quantitative SPECT/CT in vivo is feasible but could benefit from improved reconstruction methods and a more sophisticated scatter compensation method .
In this study, OSEM-based reconstruction package was validated for 177Lu radionuclide using realistic anthropomorphic torso phantom measurements. The quantitation accuracy of the reconstruction package was determined using different sized spherical inserts in the torso phantom. Concentration recovery coefficients (cRCs) were calculated for the inserts through application of state of the art compensation methods such as Monte Carlo-based scatter correction (S), collimator-detector response (R) and CT-based attenuation correction (A) during the reconstruction. We also studied how different compensation combinations affect the fundamental dosimetric parameters such as the effective half-life and absorbed dose estimates using clinical 177Lu-DOTATATE-treated patient data.
Our study is composed of two different parts: (i) determining the 177Lu quantification accuracy of our reconstruction package using a torso phantom and (ii) reconstruction of patient data with different compensation combinations and determination of absorbed dose estimates for kidneys. All the phantom and patient data were acquired, reconstructed and analysed in a similar way, and the details are given in the following sections.
SPECT/CT imaging protocol
Images were acquired on a SPECT/CT system (Symbia T2, Siemens Healthcare, Erlangen, Germany) using the local clinical imaging protocol for 177Lu-therapy patients. The SPECT acquisition included the following parameters: 64 projections, 20 s per projection, a non-circular step-and-shoot acquisition orbit, 128 × 128 matrix and 4.8 mm pixel size. Projection data were acquired using a 20 % energy window centred on the 208 keV photopeak using a parallel-hole medium energy low penetration (MELP) collimator. After the SPECT acquisition, a CT scan was performed using the CT tube voltage of 130 keV and a quality reference tube current-time product of 100 mAs (CareDose 4D). The calculated CTDIvol was 10.8 mGy, and the CT scans covered one or two SPECT field of views (40 cm per view) depending on the case. CT data was reconstructed to 512 × 512 matrix with 0.98 × 0.98 mm pixel size and 3.0 mm slice thickness. The CT reconstruction was performed using two different kernels: smoother kernel (B08s) for attenuation correction and scatter correction and sharper kernel (B35) for volume of interest (VOI) delineation.
All images were reconstructed with an OSEM algorithm with 15 iterations and 16 subsets. Compensations for attenuation and collimator-detector response were applied as described in . Briefly, the CT attenuation map was generated using a bilinear conversion for HU to linear attenuation coefficient values, and collimator correction was based on the Gaussian convolution. The scatter correction was implemented using an accelerated Monte Carlo (MC) simulation method . Because MC scatter simulations are time-consuming, the scatter correction was accelerated with convolution-based forced detection and calculation of the scattering into a sparser matrix than the resulting image. The scatter estimate was calculated for only the first two iterations, and the scattering was modelled only during forward projection.
All SPECT reconstructions produced images with 128 × 128 matrix with 128 slices and 4.8 × 4.8 × 4.8 mm3 voxel size. Each data set was compensated separately for attenuation (A), attenuation and collimator-detector response (AR) and attenuation, collimator-detector and scatter (ARS). Attenuation and scatter correction (AS) was not implemented, because the convolution-based forced detection scatter correction method inherently includes collimator and detector modelling. We think that omitting collimator-detector modelling for primary photons but applying it for scatter photons is illogical. Post-filtering was not applied to any of the data presented in this study. The reconstruction methods used in this work were implemented into the reconstruction engine of a commercially available reconstruction package, HERMES HybridRecon version 1.1 (HERMES Medical Solutions AB, Stockholm, Sweden).
The volume and activities as well as the locations of the tumour inserts in the torso phantom
Location in phantom
Next to active left lung
Next to non-active right lung
After inserting lung and spherical inserts, the phantom was filled with 177Lu activity to make imaging and analysis processes more representative of patient studies. The inserts and left lung concentrations were 30 and 1.7 times greater than the background, respectively. The total activity in the phantom was 806 MBq during imaging.
The SPECT/CT scanner was calibrated using a calibration phantom as suggested in MIRD Pamphlet no. 23 . A bottle (diameter 6.6 cm, height 15.3 cm and volume of 525 cm3) was filled with homogeneous 177Lu solution with an activity concentration of 0.45 MBq/cm3, and it was placed inside the cylindrical body of the Jaszczak phantom filled with water. For each reconstruction parameter set, a VOI was drawn manually over the bottle based on the dimensions of the bottle and the CT images. The volumetric sensitivity Ŝ vol (kBq/ml) of the SPECT/CT system was determined as reported by Sanders et.al . During the study, the Ŝ vol values were used to convert torso phantom and patient SPECT images to activity concentration distributions.
Patient data characteristics
SPECT/CT imaging time (h)
Delineated kidney VOI volumes (ml)
Data analysis and absorbed dose calculations
where R insert is the count density within the defined VOI, Vinsert is the VOI volume and Cinsert is the true concentration in the insert. cRC was calculated for each insert and each compensation method.
The total number of decays within the kidney volume was determined as an analytical integral of the fitted exponential function from the time of injection (t = 0) to infinity. The total number of decays was converted to absorbed dose by taking into account only the self-dose produced by electrons . The absorbed dose estimates, D, were compared between compensation method combinations.
The torso phantom study
The cRC results for A, AR and ARS compensation combinations as a function of the insert volume are shown in Fig. 2. From this figure, we can see how cRC is dependent on the size of the insert because of the limited spatial resolution of the SPECT system. Since the collimator-detector response compensation method can partly compensate for the resolution loss the dependence gets weaker as more compensation methods are applied during reconstruction. The ARS method produced the highest recovery values for all spheres; the gain was dependent on the insert size and ranged from 200 % for small inserts to 35 % for the largest inserts when compared to A method. None of the methods could recover the true concentration (cRC = 1) for any of the inserts, because VOIs were drawn based on the CT image and physical boundaries and no partial volume correction was attempted.
In this study, we have validated the quantitative accuracy of our reconstruction package for 177Lu using an anthropomorphic phantom. We determined cRC values from nine spherical sources with varying sizes using different compensation method combinations applied during reconstructions. Applying collimator-detector response compensation dramatically improves cRC compared with the attenuation corrected only images. In addition to the collimator-detector response compensation method, the MC simulation-based scatter correction method improved quantitation accuracy even more, especially for small sources.
Our results are comparable with recently published studies [12, 14]. In a recent study, Sanders et al. reported the cRC being around 80 % for the 16-ml spherical source, while we found cRC to be 75 and 85 % for sources with size of 11.5 and 26.2 ml, respectively (Fig. 2). For the small inserts like Q7 with volume of 2.6 ml, the ARS method produced cRC of 70 %, which is as high as Sanders et.al reported for the sources with volume from 4 to 8 ml.
From the patient data, we found a similar trend in absorbed doses as with the cRC values: ARS produced the highest absorbed dose estimates between the methods evaluated in this study due to systematically higher activity estimates at every acquisition time point. For example in eight out of ten cases, ARS produced over 20 % higher estimated absorbed doses into the left or right kidney than method A, and in patient P9 case, ARS produced up to 40 % higher estimated dose than method A. In general, the absorbed doses to kidneys ranged from 1.3 to 5 Gy. Similar dose ranges have been reported earlier [2, 3]. Considering 23 Gy absorbed dose limit to the kidneys derived from external radiotherapy, the difference between reconstruction methods can be considered to be clinically relevant. In other words, for an individual patient, the number of treatment cycles can depend on what reconstruction method has been used during dose calculations.
Frequently, in patients with liver metastatic neuroendocrine tumours, the distinction between the right kidney and liver metastases’ 177Lu-DOTATATE activity distributions is challenging to make due to the poor spatial resolution of SPECT systems. In this study, we have shown how the collimator-detector compensation method can help with these kinds of cases. In patient P2, ARS produced 24 % smaller absorbed doses to the right kidney than A, but it was clearly due to an improved distinction between kidney and liver activity distributions and reduced spill in from liver volume to the kidney.
In our study, we have delineated the VOIs based on CT image and tracked the physical boundaries of either inserts or kidneys. The method is arguably cumbersome and sensitive to partial volume effect (PVE). Some of the authors of previous studies have used a so-called a small VOI method , where a small VOI is used to sample activity within the whole kidney. The small VOI method is easy to implement and is at least justifiable for cases like the patient P2, where a clear distinction between activity distributions is difficult to make. However, the small VOI gives a limited sample of the kidney’s activity distribution, and thus, the dose calculation is carried out using a small and manually selected representative VOI statistics. Because the selection of the small VOI is not always unambiguous, in clinical practice, dose calculation is compromised, for example, to represent only the maximum dose of the kidney, and it does not take activity heterogeneity into account. In addition to this, to carry out the patient-specific dose calculation, the kidney masses should be delineated patient specifically; thus, whole kidney delineation was preferred in our study.
Applying attenuation, collimator-detector and Monte Carlo scatter compensation methods (ARS) improved cRC especially in small-sized sources which might aid tumour dosimetry for 177Lu PRRT treatments. From the patient data, we observed that 177Lu-DOTATATE half-life estimates did not apparently depend on reconstruction compensation methods.
This study was supported by the Instrumentarium tiedesäätiö (The Instrumentarium Science Foundation) (2012–2013)
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.View ArticlePubMedGoogle Scholar
- Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25. doi:10.1007/s002590100574.View ArticlePubMedGoogle Scholar
- Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nuclear Med. 2013;54:33–41. doi:10.2967/jnumed.112.107524.View ArticleGoogle Scholar
- Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B et al. Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nuclear Med. 2015:jnumed.114.148437-. doi:10.2967/jnumed.114.148437.
- Hippelainen E, Tenhunen M, Sohlberg A. Fast voxel-level dosimetry for Lu labelled peptide treatments. Phys Med Biol. 2015;60(17):6685–700. doi:10.1088/0031-9155/60/17/6685.View ArticlePubMedGoogle Scholar
- Bardies M, Flux G, Lassmann M, Monsieurs M, Savolainen S, Strand S. Quantitative imaging for clinical dosimetry. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2006;569:467–71. doi:doi: 10.1016/j.nima.2006.08.068.
- Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37:212–25. doi:10.1007/s00259-009-1216-8.View ArticlePubMedGoogle Scholar
- Shcherbinin S, Celler A, Belhocine T, Vanderwerf R, Driedger A. Accuracy of quantitative reconstructions in SPECT/CT imaging. Phys Med Biol. 2008;53:4595–604. doi:10.1088/0031-9155/53/17/009.View ArticlePubMedGoogle Scholar
- Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601–9. doi:10.1109/42.363108.View ArticlePubMedGoogle Scholar
- Dewaraja YK, Frey EC, Sgouros G, Brill B, Roberson P, Zanzonico PB, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310–25. doi:10.2967/jnumed.111.100123.PubMed CentralView ArticlePubMedGoogle Scholar
- Shcherbinin S, Piwowarska-Bilska H, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/90Y targeted radionuclide therapies. Phys Med Biol. 2012;57:5733. doi:10.1088/0031-9155/57/18/5733.View ArticlePubMedGoogle Scholar
- Sanders JC, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT/CT imaging of Lu-177 with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17(4):585–93. doi:10.1007/s11307-014-0806-4.View ArticlePubMedGoogle Scholar
- de Nijs R, Lagerburg V, Klausen TL, Holm S. Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections. Nucl Med Commun. 2014;35(5):522–33. doi:10.1097/MNM.0000000000000079.PubMed CentralView ArticlePubMedGoogle Scholar
- Beauregard J-M, Hofman M, Pereira J, Eu P, Hicks R. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66. doi:10.1102/1470-7330.2011.0012.PubMed CentralView ArticlePubMedGoogle Scholar
- Zeintl J, Vija A, Yahil A, Hornegger J, Kuwert T. Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med. 2010;51:921–8. doi:10.2967/jnumed.109.071571.View ArticlePubMedGoogle Scholar
- Sohlberg A, Watabe H, Iida H. Three-dimensional SPECT reconstruction with transmission-dependent scatter correction. Ann Nucl Med. 2008;22:549–56. doi:10.1007/s12149-008-0170-z.View ArticlePubMedGoogle Scholar
- Sohlberg A, Watabe H, Iida H. Acceleration of Monte Carlo-based scatter compensation for cardiac SPECT. Phys Med Biol. 2008;53:N277–85. doi:10.1088/0031-9155/53/14/n02.View ArticlePubMedGoogle Scholar